Clareo Health | Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Virion Therapeutics
With
Vir Biotechnology, Inc.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Documented chronic HBV infection (eg, HBsAg+ ≥ 6 months with detectable HBsAg at screening)
2. Receipt of either entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine for at least 12 months before screening with no reported antiviral resistance during this time; still on treatment at screening and expected to stay on therapy during the study period
3. Virally suppressed for \> 12 months (HBV DNA \< 40 IU/mL)
4. No clinical diagnosis of advanced liver fibrosis and/or cirrhosis
You may not be if
1. History of hepatic decompensation, advanced fibrosis, or liver transplantation
2. History of hepatocellular carcinoma
3. History of risk factors for thrombosis and thrombocytopenia
4. Documented hepatitis A, hepatitis C, hepatitis D, hepatitis E, or HIV (or history of prior active disease)
5. Pregnant, nursing, or planning a pregnancy during the trial
